We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » U.S. FDA Proposes Naming Convention for Biosimilars, Reference Products
U.S. FDA Proposes Naming Convention for Biosimilars, Reference Products
The U.S. Food and Drug Administration released long-awaited draft guidance on Aug. 27 on naming biological products, proposing that both reference products and biosimilars have nonproprietary names comprised of the core drug substance name and a different four-letter suffix.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor